‘Critical Step’ For Petros Toward ED Switch Proposal With OTC Label Comprehension Study

Firm reports “significant comprehension” among 480 participants. It also expects DFL technology it’s developing for potential OTC sales of Stendra ED drug could be used for other OTC switch proposals.

Petros Pharmaceuticals anticipates Drug Facts label technology it’s developing for potential switch of its Stendra ED drug also could be used for other OTC switch proposals. • Source: Petros Pharmaceuticals

Petros Pharmaceuticals, Inc. expects a recent label comprehension study to move it closer to an Rx-to-OTC switch of its Stendra erectile dysfunction drug, a project it has increased research spending on by nearly $500,000 in the past year.

The New York firm also expects the Drug Facts label technology it’s developing for potential OTC sales of its avanafil...